利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

162 条记录 (耗时 0.055 秒)

    PHARMACEUTICAL DIAGNOSTIC
    93.
    发明公开
    PHARMACEUTICAL DIAGNOSTIC 审中-公开
    药剂师诊断

    公开(公告)号：EP2830621A1

    公开(公告)日：2015-02-04

    申请号：EP13715169.2

    申请日：2013-03-27

    申请人： Novartis AG

    发明人： FURET, Pascal ,  FRITSCH, Christine ,  MAIRA, Sauveur-Michel

    IPC分类号： A61K31/4439 ,  A61P35/00 ,  C12Q1/68 ,  G11B20/00 ,  C12N15/11

    摘要： The present invention relates to selective cancer treatment regimes based on assaying for the presence or absence of a glutamine or a nucleic acid that encodes glutamine at position 859 of the catalytic p110α subunit of PI3K; methods for producing a transmittable form of information for predicting the responsiveness of patient to (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or a pharmaceutically acceptable salt thereof; and a kit thereof.

    摘要翻译： 本发明涉及基于测定PI3K的催化性p110α亚基的位置859上谷氨酰胺或编码谷氨酰胺的核酸的存在或不存在的选择性癌症治疗方案; 用于产生用于预测患者对（S） - 吡咯烷-1,2-二羧酸2-酰胺1 - （{4-甲基-5- [2-（2,2,2-三氟乙基） 三氟-1,1-二甲基 - 乙基） - 吡啶-4-基] - 噻唑-2-基} - 酰胺）或其药学上可接受的盐; 及其套件。

    BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS
    100.
    发明授权
    BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS 有权
    恶唑和恶唑詹纳斯激酶抑制剂

    公开(公告)号：EP2066647B1

    公开(公告)日：2011-11-09

    申请号：EP07802300.9

    申请日：2007-09-13

    申请人： Novartis AG

    发明人： GERSPACHER, Marc ,  FURET, Pascal ,  VANGREVELINGHE, Eric

    IPC分类号： C07D263/58 ,  C07D413/04 ,  C07D498/04 ,  A61K31/423 ,  A61K31/4439 ,  A61K31/4725 ,  A61K31/4709 ,  A61K31/5377 ,  A61K31/437 ,  A61P35/00

    CPC分类号： C07D263/58 ,  C07D413/04

    摘要： The invention relates to 2,7-disubstituted benzoxazole and 2,4-disubstituted oxazolo[5,4- c]pyridine compounds of the formula I given below, as well as salts thereof, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, these compounds for use in the treatment (including prophylaxis) of the animal, especially human, body (especially with regard to a proliferative disease), the use thereof - alone or in combination with one or more other pharmaceutically active compounds - for the treatment especially of a protein tyrosine kinase mediated disease (such as a tumor disease) or for the manufacture of a pharmaceutical preparation for use in the treatment of such a disease, a method for the treatment of such a disease and a pharmaceutical preparation for the treatment of a disease as mentioned. The compounds are of the formula I, wherein the symbols are as defined in the description. The compounds inhibit, for example, JAK2 and JAK3.